Chemical subgroup
J06BD – Antivirale monoklonale Antikörper
7Decisions
14Patient groups
Added benefit by patient group
- Considerable2
- Minor1
- Not proven11
Decisions, newest first
- 2025-08-21BeyfortusNirsevimabConsiderable
- 2025-08-07KavigaleSipavibartNot proven: 2 of 2 patient groups
- 2025-02-20BeyfortusNirsevimabNot proven: 2 of 2 patient groups
- 2024-08-15BeyfortusNirsevimabNot proven: 2 of 2 patient groups
- 2023-11-02EvusheldTixagevimab/CilgavimabNot proven
- 2023-04-20EvusheldTixagevimab/CilgavimabMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2022-11-03XevudySotrovimabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
Data status: 2026-10-29